Global Non-insulin Diabetes Therapeutics Market Forecasts to 2022 - Key Players are AstraZeneca, Eli Lilly, Merck, Novo Nordisk, Sanofi - ResearchAndMarkets.com

DUBLIN--()--The "Global Non-insulin Diabetes Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The global non-insulin diabetes therapeutics market to grow at a CAGR of 11.37% during the period 2018-2022.

The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is innovations in therapies. The development of innovative therapies will provide traction to the growth of the non-insulin diabetes therapeutics market. Vendors in the type 2 non-insulin therapies market are opting for advanced therapies including incretins-based type 2 diabetes drugs. Incretins are secreted by the GI tract in response to food intake.

According to the report, one driver in the market is increasing number of people with type 2 diabetes. The body's ineffective use of the insulin produced renders in the occurrence of type 2 diabetes. Several individuals are suffering from type 2 diabetes globally, due to causes such as excess body weight and physical inactivity.

Further, the report states that one challenge in the market is high barriers to entry. Several stringent regulations have been imposed on non-insulin diabetes therapeutics by organizations such as the USFDA, the ADA and the EASD.

Key Vendors

  • AstraZeneca
  • Eli Lilly
  • Merck
  • Novo Nordisk
  • Sanofi

Key Topics Covered

1. Executive Summary

2. Scope of the Report

3. Research Methodology

4. Market Landscape

5. Market Sizing

6. Five Forces Analysis

7. Market Segmentation by Type

8. Customer Landscape

9. Regional Landscape

10. Decision Framework

11. Drivers and Challenges

12. Market Trends

13. Vendor Landscape

14. Vendor Analysis

For more information about this report visit https://www.researchandmarkets.com/research/pdppbr/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs